Journal
CANCER CELL
Volume 31, Issue 4, Pages 476-485Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2017.03.002
Keywords
-
Categories
Funding
- Stand Up To Cancer grant (St. Baldrick's Pediatric Dream Team Translational Research Grant) [SU2C-AACR-DT1113]
- Parker Institute for Cancer Immunotherapy
Ask authors/readers for more resources
Cancer immunotherapies can be classified into agents that amplify natural immune responses (e.g., checkpoint inhibitors) versus synthetic immunotherapies designed to initiate new responses (e.g., monoclonal antibodies [mAbs], chimeric antigen receptors [CARs]). Checkpoint inhibitors mediate unprecedented benefit in some adult cancers, but have not demonstrated significant activity in pediatric cancers, likely due their paucity of neoantigens. In contrast, synthetic immunotherapies such as mAbs and CAR T cells demonstrate impressive effects against childhood cancers. Intense efforts are underway to enhance the effectiveness of pediatric cancer immunotherapies through improved engineering of synthetic immunotherapies and by combining these with agents designed to amplify immune responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available